Klein Herenbrink C[au] - Search Results

Year	Number of Results
2011	1
2012	1
2014	1
2015	1
2016	1
2017	1
2018	2
2019	1
2020	1
2022	1

1

Molecular Determinants of the Intrinsic Efficacy of the Antipsychotic Aripiprazole.

Klein Herenbrink C, Verma R, Lim HD, Kopinathan A, Keen A, Shonberg J, Draper-Joyce CJ, Scammells PJ, Christopoulos A, Javitch JA, Capuano B, Shi L, Lane JR. Klein Herenbrink C, et al. ACS Chem Biol. 2019 Aug 16;14(8):1780-1792. doi: 10.1021/acschembio.9b00342. Epub 2019 Aug 5. ACS Chem Biol. 2019. PMID: 31339684 Free PMC article.

2

Novel Fluorescent Ligands Enable Single-Molecule Localization Microscopy of the Dopamine Transporter.

Guthrie DA, Klein Herenbrink C, Lycas MD, Ku T, Bonifazi A, DeVree BT, Mathiasen S, Javitch JA, Grimm JB, Lavis L, Gether U, Newman AH. Guthrie DA, et al. Among authors: klein herenbrink c. ACS Chem Neurosci. 2020 Oct 21;11(20):3288-3300. doi: 10.1021/acschemneuro.0c00397. Epub 2020 Oct 1. ACS Chem Neurosci. 2020. PMID: 32926777 Free PMC article.

3

The role of kinetic context in apparent biased agonism at GPCRs.

Klein Herenbrink C, Sykes DA, Donthamsetti P, Canals M, Coudrat T, Shonberg J, Scammells PJ, Capuano B, Sexton PM, Charlton SJ, Javitch JA, Christopoulos A, Lane JR. Klein Herenbrink C, et al. Nat Commun. 2016 Feb 24;7:10842. doi: 10.1038/ncomms10842. Nat Commun. 2016. PMID: 26905976 Free PMC article.

4

The action of a negative allosteric modulator at the dopamine D₂ receptor is dependent upon sodium ions.

Draper-Joyce CJ, Verma RK, Michino M, Shonberg J, Kopinathan A, Klein Herenbrink C, Scammells PJ, Capuano B, Abramyan AM, Thal DM, Javitch JA, Christopoulos A, Shi L, Lane JR. Draper-Joyce CJ, et al. Among authors: klein herenbrink c. Sci Rep. 2018 Jan 19;8(1):1208. doi: 10.1038/s41598-018-19642-1. Sci Rep. 2018. PMID: 29352161 Free PMC article.

5

Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission.

Yarwood RE, Imlach WL, Lieu T, Veldhuis NA, Jensen DD, Klein Herenbrink C, Aurelio L, Cai Z, Christie MJ, Poole DP, Porter CJH, McLean P, Hicks GA, Geppetti P, Halls ML, Canals M, Bunnett NW. Yarwood RE, et al. Among authors: klein herenbrink c. Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):12309-12314. doi: 10.1073/pnas.1706656114. Epub 2017 Oct 30. Proc Natl Acad Sci U S A. 2017. PMID: 29087309 Free PMC article.

6

Multimodal detection of dopamine by sniffer cells expressing genetically encoded fluorescent sensors.

Klein Herenbrink C, Støier JF, Reith WD, Dagra A, Gregorek MAC, Cola RB, Patriarchi T, Li Y, Tian L, Gether U, Herborg F. Klein Herenbrink C, et al. Commun Biol. 2022 Jun 10;5(1):578. doi: 10.1038/s42003-022-03488-5. Commun Biol. 2022. PMID: 35689020 Free PMC article.

7

The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D₂ receptor.

Draper-Joyce CJ, Michino M, Verma RK, Klein Herenbrink C, Shonberg J, Kopinathan A, Scammells PJ, Capuano B, Thal DM, Javitch JA, Christopoulos A, Shi L, Lane JR. Draper-Joyce CJ, et al. Among authors: klein herenbrink c. Biochem Pharmacol. 2018 Feb;148:315-328. doi: 10.1016/j.bcp.2018.01.002. Epub 2018 Jan 9. Biochem Pharmacol. 2018. PMID: 29325769 Free PMC article.

8

Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand.

Mistry SN, Shonberg J, Draper-Joyce CJ, Klein Herenbrink C, Michino M, Shi L, Christopoulos A, Capuano B, Scammells PJ, Lane JR. Mistry SN, et al. Among authors: klein herenbrink c. J Med Chem. 2015 Sep 10;58(17):6819-43. doi: 10.1021/acs.jmedchem.5b00585. Epub 2015 Aug 28. J Med Chem. 2015. PMID: 26258690 Free article.

9

Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.

Szabo M, Klein Herenbrink C, Christopoulos A, Lane JR, Capuano B. Szabo M, et al. Among authors: klein herenbrink c. J Med Chem. 2014 Jun 12;57(11):4924-39. doi: 10.1021/jm500457x. Epub 2014 May 30. J Med Chem. 2014. PMID: 24827597

10

A novel nonribose agonist, LUF5834, engages residues that are distinct from those of adenosine-like ligands to activate the adenosine A(2a) receptor.

Lane JR, Klein Herenbrink C, van Westen GJ, Spoorendonk JA, Hoffmann C, IJzerman AP. Lane JR, et al. Among authors: klein herenbrink c. Mol Pharmacol. 2012 Mar;81(3):475-87. doi: 10.1124/mol.111.075937. Epub 2011 Dec 21. Mol Pharmacol. 2012. PMID: 22188926

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results